Refractory Tumor clinical trials at UCSD
1 in progress, 0 open to eligible people
Sorry, not currently recruiting here
This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.
San Diego, California and other locations